RxDoctor Payments Data

Ally Kaputa

Physician Assistant · Greensburg, PANPI 1548942907

Payments from drug & device makers

$3,693in general payments, 2019–2025

Across 192 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Eisai Inc.$473
  • Acadia Pharmaceuticals Inc$403
  • Vanda Pharmaceuticals Inc.$220
  • MDD US Operations, LLC$210
  • Pfizer$201
  • plus $855 from 15 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$3,675100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,693 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,505
Medicare patients
62
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide21$184,147
Teriflunomide12$70,800
Nurtec OdtRimegepant Sulfate51$50,310
QuliptaAtogepant38$42,344
UbrelvyUbrogepant32$41,441
Aimovig AutoinjectorErenumab-Aooe36$40,884
Emgality PenGalcanezumab-Gnlm37$28,039
BriviactBrivaracetam12$13,377
Memantine Hcl204$6,440
Carbidopa-LevodopaCarbidopa/Levodopa170$5,879
Rivastigmine39$4,380
Levetiracetam166$4,308
TegretolCarbamazepine11$4,039
Gabapentin222$3,625
Carbidopa-Levodopa ErCarbidopa/Levodopa54$3,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$20$184,14721 claims
AbbVieQulipta, Ubrelvy$1,332$83,78570 claims
PfizerNurtec Odt$201$50,31051 claims
UCB, Inc.Briviact$44$13,37712 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$39$66419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →